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Abstract: Dengue virus (DENV) presents a significant threat to global public health with more
than 500,000 hospitalizations and 25,000 deaths annually. Currently, there is no clinically approved
antiviral drug to treat DENV infection. The envelope (E) glycoprotein of DENV is a promising target
for drug discovery as the E protein is important for viral attachment and fusion. Understanding
the structure and function of DENV E protein has led to the exploration of structure-based drug
discovery of antiviral compounds and peptides against DENV infections. This review summarizes
the structural information of the DENV E protein with regards to DENV attachment and fusion.
The information enables the development of antiviral agents through structure-based approaches.
In addition, this review compares the potency of antivirals targeting the E protein with the antivirals
targeting DENV multifunctional enzymes, repurposed drugs and clinically approved antiviral drugs.
None of the current DENV antiviral candidates possess potency similar to the approved antiviral
drugs which indicates that more efforts and resources must be invested before an effective DENV
drug materializes.
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1. Introduction
Dengue virus (DENV) infection is the most prevalent arboviral disease with 390 million infections
occurring annually, of which 96 million infections were manifested clinically [1]. Infection with
any of the four DENV serotypes (DENV1-4) can produce a range of clinical manifestations, from a
mild flu-like illness to life-threatening severe diseases known as dengue haemorrhagic fever (DHF)
and dengue shock syndrome (DSS) in some individuals. Vaccines and antiviral therapies are being
developed to prevent or treat DENV infection. The development of DENV vaccines has made significant
progress with the licensing of CYD-TDV (Dengvaxia) in 20 countries including Philippines, Mexico,
Brazil, El Salvador, Indonesia, Costa Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore since
2015 [2,3]. However, Dengvaxia has failed to provide complete protection with serotype-specific
efficacy of 51% for DENV1, 34% for DENV2, 75% for DENV3 and 77% for DENV4 [4]. Furthermore,
the vaccine only exhibited good efficacy in seropositive individuals (60%–76% efficacy) and not in
seronegative individuals (19%–39% efficacy) [5]. Dengvaxia was shown to increase the risk of dengue
hospitalizations in seronegative vaccinees in comparison to unvaccinated seronegative individuals [6].
An increased risk of severe dengue has also been observed in seronegative vaccine recipients during
subsequent infection with other heterologous DENV serotypes [5].
Similarly, the development of effective antiviral agents against DENV infection is being widely
pursued. The discovery of antiviral agents against DENV was performed using multiple strategies
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such as the screening of natural compounds, small molecules, nucleoside analogues and chemical
libraries. Additionally, there is a resurgence in the peptide-based drug research to develop effective
antiviral peptides against viruses following the success of the commercially available enfuvirtide [7].
Enfuvirtide is a 36 amino acid peptide that mimics a region within the human immunodeficiency virus
HIV-1 envelope glycoprotein 41 (gp41). Enfuvirtide blocks the fusion of HIV-1 and cellular membranes
by binding to the HIV gp41.
2. DENV Genome and Encoded Proteins
DENV is a member of the Flaviviridae family. Its genome comprises a single-stranded positive-sense
RNA of approximately 11 kb that encodes a polyprotein [8]. The polyprotein is cleaved by proteases
into three structural proteins which are the nucleocapsid protein (C), envelope glycoprotein (E) and
precursor membrane (prM) proteins, and seven non-structural proteins which are NS1, NS2A, NS2B,
NS3, NS4A, NS4B and NS5 (Figure 1) [9]. The structural proteins form the virus particle with both prM
and E being located at the surface while the C protein is located inside the envelope. The C protein
is important for encapsidation that protects the DENV genome [10]. The prM maintains the spatial
structure of the E protein [11]. The E protein has been implicated in the membrane fusion between
host cells and DENV particles [11]. Importantly, non-structural proteins regulate various stages of the
DENV lifecycle, including viral RNA replication, virion assembly, polyprotein cleavage, maturation,
and defense against host immunity [12–15]. Antiviral development approaches thus far have targeted
both structural and non-structural proteins, with the main focus on multifunctional enzymes such as
NS3, NS4B and NS5 [16–20].
Figure 1. Schematic representation of the DENV genome and the encoded proteins.
3. Current Status of Dengue Antiviral Development
Severe dengue including DHF and DSS are associated with a fatality rate as high as 15% in
the absence of proper medical attention [21]. Supportive fluid therapy remains the only available
treatment for severe dengue [22]. Therefore, there is an unmet need to develop a safe and effective
DENV antiviral. The main rationale for the development of a DENV antiviral is to reduce viremia
during the early phase of the infection, which is expected to prevent progression to DHF/DSS [23,24].
An ideal dengue antiviral must significantly reduce the viral load within 70 h of illness onset to prevent
disease progression to DHF or DSS [24]. Furthermore, the drug should inhibit all four DENV serotypes
as these serotypes could co-circulate in endemic areas [25,26].
3.1. Drug Repurposing for Dengue Therapy
A panel of drugs initially developed for other viral and non-viral diseases have been evaluated
for their activities against DENV (Table 1). Drug repurposing strategy is favorable as it takes a shorter
time and less cost to reach the clinic [27]. Many of the repurposed drugs have been evaluated for their
efficacies to treat dengue patients. Four of the drugs (balapiravir, celgosivir, UV4B and ivermectin)
exhibited sub-µM in vitro potency against DENVs, justifying their evaluations in the clinical trials
(Table 1). Reductions in viremia and NS1 antigenaemia were used as the main endpoints in these
clinical trials [20,28–31].
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Table 1. Repurposed drugs evaluated in clinical trials.
Compound The Rationale for DrugRepurposing
In Vitro
Potency
Clinical Trial Status and
Results Ref
Chloroquine
Inhibited DENV entry
and replication in vitro
and in vivo.
N/A
No reduction in viremia
and NS1 antigenaemia
(ISRCTN38002730).
Reduced pain intensity in
patients (NCT00849602).
[28,32–36]
Prednisolone
Corticosteroid therapy
could prevent the
development of serious
dengue complications.
N/A
No reduction in the
development of
complications of dengue
(ISRCTN39575233).
[29,37]
Lovastatin
Exhibited modest
inhibition of DENV2
replication in A549 cells.
Protected mice from
DENV2 infection.
EC50: 6.20 µM
No reduction in viremia
(ISRCTN03147572).
Minimal effect on dengue
severity.
[30,38–43]
Modipafant
Inhibitor of
platelet-activating factor
receptor. Protective
against lethal DENV2
challenge in mice.
N/A The clinical trial is ongoing(NCT02569827) [44]
Ketotifen
Exhibited inhibition of
the DENV3-induced cell
degranulation. Limits
vascular leakage in
mouse models of
DENV2 infection.
N/A Data not yet available(NCT02673840). [45,46]
Balapiravir Inhibited DENV4 RNAsynthesis in vitro. IC50: 0.89 µM
No reduction in viremia
levels and NS1
antigenaemia
(NCT01096576).
[20,47]
Ribavirin
Demonstrated
synergistic effects in
combination with an
imino sugar CM-10-18 to
suppress DENV2
replication in vitro and
in the murine model.
EC50: 3 µM
Evaluated in combination
with Chinese herbal drug
(NCT01973855). Data are
not yet available.
[48–51]
Celgosivir
Exhibited sub-µM
in vitro anti-DENV1-4
activity and protective
against DENV2 lethal
challenge in mice.
EC50: 0.22- 0.68
µM
No significant reduction of
viremia or fever burden
(NCT01619969). Phase 2a
clinical trial with an
altered regimen of
celgosivir is ongoing
(NCT02569827).
[31,52–55]
UV-4B
Exhibited inhibition of
DENV1-4 in vitro.
Protective against lethal
DENV2 challenge in
mice.
IC50: > 0.47 µM
Clinical trial terminated
due to business reasons
(NCT02696291).
[56–58]
Ivermectin Inhibited DENV2replication in vitro. IC50: 0.5 µM
Initial unpublished
findings suggest no
reduction in viremia
(NCT02045069).
[59–61]
N/A: Not available or not applicable. EC50: half-maximal effective concentration. IC50: half-maximal
inhibitory concentration.
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Chloroquine was evaluated against DENV due to its ability to inhibit endosomal acidification.
This potentially interferes with the fusion of viral and endosomal membranes. In vitro studies showed
that chloroquine inhibited DENV1 replication in THP cells overexpressing DC-SIGN and DENV2
replication in U937 and Vero cells [32–34]. Furthermore, chloroquine was shown to reduce viremia
in monkeys infected with DENV2 [36]. Despite the promising pre-clinical findings, chloroquine did
not reduce viremia and NS1 antigenaemia in dengue patients [28]. Chloroquine was not efficacious
probably because it did not achieve sufficient inhibitory concentration within the reticuloendothelial
cells where DENV replication occurred [28].
Corticosteroid is mainly adopted as an adjunct immunomodulatory treatment for diseases caused
by immune responses [48]. Immune pathology of dengue has similarities to other autoimmune diseases
that have been successfully treated by corticosteroids [48,62]. A clinical trial has shown the supportive
evidence for the actions of methylprednisolone to prevent dengue progression to DHF or DSS [63].
Another clinical trial to evaluate the effects of immunomodulation by prednisolone revealed that the
treatment with oral prednisolone during the acute stage of DENV infection did not lead to prolong viral
clearance or other adverse effects [29]. However, the study also found that there was no reduction in
the development of recognized complications of DENV infection [29]. The lack of clinical benefit could
be due to limited immunomodulation achieved by prednisolone [37]. Similarly, statins were evaluated
against DENV infection due to their anti-inflammatory and immunomodulatory effects. In particular,
their stabilizing effect on vascular endothelium could be beneficial to prevent endothelial dysfunction
in dengue patients [64]. Interestingly, in vitro studies revealed that lovastatin interfered with DENV
virion assembly [38,40]. However, clinical trials revealed lovastatin did not reduce viremia in dengue
patients [30]. Modipafant and ketotifen are other drugs that have been evaluated to treat dengue fever
due to their anti-inflammatory properties. The clinical trial for modipafant (NCT02569827) is currently
ongoing while the data for the clinical trial of ketotifen (NCT02673840) are yet to be available.
Balapiravir and Ribavirin are nucleoside analogues that were originally developed as antivirals
against HCV infection. Balapiravir was found to be effective to reduce HCV viremia in dose-dependent
and time-dependent manners [65]. However, further development of balapiravir for the treatment of
chronic HCV infection has been stopped due to serious haematological adverse events observed in
patients receiving prolong (2–3 months) treatment with balapiravir [66]. Researchers have evaluated
the potential use of balapiravir as a treatment for dengue. This is due to the similarity in the
architecture of its target protein, the RNA-dependent RNA polymerases between HCV and DENV.
Although balapiravir demonstrated potent in vitro activity against DENV, no reduction in viremia
and NS1 antigenaemia were observed in adult dengue patients [20]. The failure of balapiravir in
the clinical trial could be due to the activation of peripheral blood mononuclear cells by DENV
infection. This decreased the efficiency of the conversion of balapiravir to its active form, leading to
decreased antiviral potency [47]. On the other hand, ribavirin displayed synergistic in vitro and in vivo
anti-DENV2 effects in combination with an oxygenated alkyl imino sugar derivative, CM-10-18 [49].
Ribavirin was evaluated clinically in combination with traditional Chinese medicine in China with the
data are as yet, unavailable (NCT01973855).
Iminosugars such as celgosivir and UV-4B have also been evaluated for their antiviral activities
against DENV. Both compounds exhibited potent in vitro antiviral activities against DENV1-4
(Table 1) [52,53,56]. In addition, both drugs protected mice against DENV2 lethal challenge [55,57].
The first clinical trial of celgosivir revealed that there was no significant reduction of viremia or fever
burden in dengue patients [31]. Another clinical trial to evaluate the efficacy of celgosivir with a revised
dosing regimen is currently on-going and is expected to finish in September 2020 (NCT02569827) [54].
For UV-4B, the clinical trial has been terminated due to business reasons (NCT02696291). Lastly,
the anti-parasitic drug, ivermectin, was identified to be a potent inhibitor of DENV replication [59].
However, preliminary results from a phase 2 clinical trial of ivermectin shown no reduction in viremia,
despite exhibiting in vitro potency in the high nM range (500 nM). This suggested that compounds
with higher in vitro potency (low nM to pM range) might provide better pharmaceutical properties.
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3.2. Approved Drugs against Viruses in the Flaviviridae Family
There is no clinically approved drug against viruses within the Flaviviridae family except against
the hepatitis C virus (HCV) [67]. Seven direct-acting antivirals have been approved by the Food
and Drug Administration (FDA) for the treatment of chronic HCV infection [68]. Three combination
regimens are effective against all HCV genotypes: (1) sofosbuvir and velpatasvir, (2) sofosbuvir,
velpatasvir, and voxilaprevir and (3) glecaprevir and pibrentasvir [68]. Each of these drugs targets
either NS5A, NS5B or NS3/4A. Sofosbuvir is an inhibitor of HCV NS5B polymerase. Its triphosphate
exhibited potent inhibitory activity against NS5B with a Ki (inhibitory constant) of 0.42 µM [69].
Velpatasvir and pibrentasvir are pan-genotypic inhibitors of HCV NS5A with EC50 values in the
range of 1 to 130 pM and 1.4 to 5.0 pM, respectively [70]. Voxilaprevir and glecaprevir are potent
pan-genotypic HCV NS3/4A protease inhibitors with EC50 values in the range of 1–130 nM and
3.5–11.3 nM, respectively [71,72]. Importantly, the pre-clinical data demonstrated the high in vitro
potency (nM to pM) required for antivirals to be successful. The potency in the low nM to pM
range enables the drugs to be administered in lower dosages to achieve desired effects. Interestingly,
sofosbuvir exhibited in vitro anti-DENV2 activity with an EC50 value of 1.4µM [73]. Although the
potency of sofosbuvir against DENV is not in the nM to pM range, it could be worthwhile to evaluate
its potential as a repurposed drug to treat DENV infection in clinical settings. Another important
lesson from the success of HCV therapies is that the combination of several drugs targeting different
viral proteins could be mandatory to formulate effective anti-dengue therapies.
3.3. Antivirals Targeting Dengue Proteins
Rational dengue antiviral discovery has been pursued to identify promising clinical candidates.
The NS3/NS2B protease is one of the main target for dengue antiviral discovery with inhibitors such
as compound 35 (IC50: 0.6 µM), 42a (IC50: 0.21 µM), 45a (IC50: 0.26 µM), SK-12 (IC50: 0.98 µM) and
compound 18 (IC50: 0.38 µM) [74–77]. In addition, inhibitors of other targets such as NS3 helicase,
RNA-dependent RNA polymerase NS5 and non-enzymatic NS4B with sub-µM potency have been
discovered [78–80]. Besides, the C protein is being explored as a drug target. For instance, ST-148
inhibited DENV2 with potency in the low nM range (EC50: 30–50 nM) [81]. However, some key
challenges could impede the entry of these compounds into clinical trials. Firstly, the identification
of viral resistance towards these compounds could significantly hamper their further development.
For instance, a single amino acid mutation at position 63 of DENV2 NS4B was found to confer viral
resistance towards a highly potent NS4B inhibitor compound 1a (EC50: 0.012 µM) [80]. Secondly,
some of these compounds lacked antiviral activities against the four DENV serotypes as is the case
of compound 1a that inhibited DENV2 and 3 only [80]. Thirdly, the development of compounds
that have safety issues will be terminated. For example, an adenosine nucleoside inhibitor NITD-008
exhibited potent antiviral activities against DENV2 with an IC50 value of 0.31 µM [82]. However,
animal studies using rats and dogs revealed that two weeks of NITD-008 oral dosing led to severe
side effects in both animals such as weight loss, blood abnormalities and movement disorders [82].
Fourthly, some compounds lack potent anti-DENV activity when evaluated in a murine model. For
example, ST-610 that potently inhibited NS3 helicase (EC50: 0.272 µM) exhibited a modest reduction
of viremia (5.2 fold) in DENV2-infected mice, signifying further optimization is needed to improve
its efficacy in vivo [78]. Lastly, compounds with poor pharmacokinetic properties are not suitable
to enter clinical trials without further optimization. NITD-618 is a potent NS4B inhibitor that was
found to be active against the four DENV serotypes with EC50 values ranging from 1 to 4.1 µM [83].
Unfortunately, NITD-618 has poor pharmacokinetic properties which prevented the evaluation of
its activity in a murine model [7]. Similarly, the development of ST-148 was stopped due to limited
oral bioavailability and rapid clearance [7]. In addition, the inability of ST-610 to significantly reduce
viremia in DENV2-infected mice could be due to its poor pharmacokinetic profiles in the murine model.
Although these challenges have halted the development of some of these compounds, many other
compounds are yet to be developed and evaluated.
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4. Discovery of Antiviral Agents Targeting Dengue Envelope Glycoprotein
The inhibition of attachment and fusion is another feasible strategy to neutralize DENV infection.
The E glycoprotein is the main mediator of DENV attachment and fusion. It belongs to a class II viral
membrane fusion protein [84]. The E protein adopts two main conformations which are 1) dimeric in
mature DENV and 2) trimeric in the immature DENV and in the acidic environment of the endosome
during fusion (Figure 2). In the mature virion, the antiparallel dimeric E proteins lay flat on the virion
surface [85,86]. In the immature DENV and fusion intermediates, the E proteins form trimers that are
pointing away from the DENV membrane, giving the virion a spiky appearance. The E protein is
composed of three ‘discontinuous’ distinct domains in the N-terminal region (Figure 2A). The central
domain 1 or EDI is formed by eight β-strand barrels. The domain 2 or EDII is an elongated domain
containing a fusion loop that is conserved among all flaviviruses. Three hydrophobic amino acids
(W101, L107 and F108) within the fusion loop are essential for the insertion of trimeric E protein into
the endosomal membrane during fusion [87]. These residues are exposed at the tip of the trimeric
E protein [88]. In contrast, these residues are buried at the dimer interface in the mature virion [85].
The domain 3 or EDIII is an immunoglobulin-like domain that is responsible for the cellular receptor
binding [89]. EDIII connects the three N-terminal domains to the stem region. The stem region is
part of the outer lipid leaflet of the viral membrane. It is composed of two α-helices connected by
a conserved sequence [90]. The position of these helices rearranges during fusion. Following the
stem region is the C-terminal transmembrane domain. This domain comprised a pair of antiparallel
coiled-coils TM1 and TM2, which contribute to the stability of the trimeric E protein and the completion
of flaviviral fusion with the endosomal membrane [91].
Figure 2. The envelope (E) glycoprotein. (A) The discontinuous domains of dengue E protein. Domain
I (EDI) is in red, domain II (EDII) is in yellow and domain III (EDIII) is in blue. The stem region and
the transmembrane (TM) domain spanning amino acids 394–495 are represented in black and white,
respectively. (B) The E protein dimer in the mature DENV2 virion and in an environment with neutral
pH (PDB ID: 1OAM). (C) The structure of trimeric DENV1 E protein in its postfusion conformation.
The domains have rotated and shifted with EDIII undergoes the most significant rearrangement with
70◦ folding towards EDI and EDII (PDB ID: 4GSX). The fusion loop is buried at the dimer interface in
mature virion. In contrast, the fusion loop is exposed at the tip of the E protein trimer in immature
virion and during fusion.
The mechanism of DENV-cellular membrane fusion has been proposed. Firstly, DENV attaches
to the cells via the interaction of its E protein with cell-surface receptors (Figure 3). Several studies
revealed that the region spanning amino acids 305 to 315 (in particular K305, K307, K310) and 382
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to 385 within EDIII carried the determinants for cellular receptor binding [94–99]. In addition, the E
protein was found to interact with β3 integrin through two regions within EDIII, spanning amino
acids 333–347 and 381–394 [100]. A complex structure of DENV binding to dendritic cell-specific
intercellular adhesion molecule-grabbing non-integrin (DC-SIGN) showed that the interaction of the
complex occurred solely through the N67 glycan of DENV and carbohydrate recognition domain
of DC-SIGN [101]. Multiple other amino acids, in particular K291 within EDI and K295 within the
EDI-EDIII hinge (based on DENV2 sequence), have been demonstrated to mediate interactions with
cellular receptors such as heparan sulfate (Figure 4) [94,102].
Figure 3. DENV attachment and fusion (PDB IDs: 1OAM and 4GSX). (A) Endocytic entry pathway of
DENV. B-E) Proposed mechanism for DENV-host cell membrane fusion. The stem region of E protein
is in white while the transmembrane anchor is in grey. The EDI, EDII and EDIII are in red, yellow
and blue, respectively. (B) The binding of E protein to the receptor leads to the internalization of the
DENV into an endosome. Reduced pH in the endosome causes the rearrangement of the E protein
from dimer to trimer. (C) During the rearrangement, the tip of the EDII hinges outwards from the
virion surface, allowing the fusion loop to be inserted into the cellular membrane to bridge cellular and
viral membranes. (D) The bending and hemifusion of the membranes are mediated by the contacts
made between EDIII-EDI and EDII-stem region. (E) Finally, the fusion loop makes contact with the
transmembrane domain, completing membrane fusion and formation of pores. Figure 3A was modified
from Hidari et. al. (2013) and Figure 3B-E was modified from Klein et. al. (2013) [92,93].
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Figure 4. Locations of the amino acids postulated to be important for DENV2 attachment to the cells.
The amino acids are shown as spheres in light grey and labelled. The EDI, EDII and EDIII are shown
in red, yellow and blue, respectively (PDB ID: 1OAM). The majority of the amino acids that were
implicated in DENV attachment to the cellular receptors are located in the EDIII.
The attached DENV will be internalized into an endosome via the clathrin-dependent process.
The reduced pH in the endosome causes E dimers on the virion surface to dissociate [85,88,93].
Subsequently, the EDII of the dissociated E protein hinges outwards from the viral surface, allowing
the interaction of the fusion loops with the target endosomal membrane [88,93,103]. The interaction of
the fusion loop with the host endosomal membrane promotes the formation of E protein trimers [104].
The trimerization process is mediated by significant domain rearrangements. During trimerization,
the EDIII rotates by about 70◦ towards the endosomal membrane and interacts with the interfaces
formed by EDI and EDII [88]. This movement brings the EDIII closer to the fusion loop. The trimers
bridge the endosomal and viral membranes (Figure 3). The driving force of the pinching of the two
membranes is mediated by the EDIII folding back to EDI and by the contacts between EDII and the
stem region (Figure 5) [93,104]. The refolding of the E protein creates bending and hemifusion of
both membranes, ultimately leading to the formation of lipidic fusion pores [105]. The pores allow
the escape of the viral nucleocapsid into the host cytosol where the expression of viral RNA genome
took place. An in-depth understanding of the attachment, entry, and fusion is paramount to design
antivirals against DENV infection.
Viruses 2020, 12, 367 9 of 23
Figure 5. Stem region interactions with the groove formed by adjacent EDIIs in the trimeric DENV1 E
protein (PDB ID: 4GSX). EDI, EDII and EDIII are represented in red, yellow and blue, respectively. The
amino acids of the stem region are represented as sticks and labelled. The key hydrophobic amino
acids of the stem region including I398, M401 and F402 interacted with the hydrophobic pocket formed
by L216, P217, L218 and M260 of the EDII [93]. The figure was modified from Klein et. al. (2013) [93].
5. Structure-Based Discovery of Antiviral Compounds Targeting the E Protein
The main advantage of targeting the E protein is that drugs can engage the E protein extracellularly
and eliminating the need to design membrane permeable drugs [106]. In addition, non-membrane
permeable drugs that target the E protein extracellularly might display low toxicity as they did not
act on intracellular proteins [107]. This is a clear advantage over drugs targeting viral enzymes
such as nucleoside analogues that were prone to target intracellular proteins and caused unwanted
off-target effects [108]. Many dengue researchers adopted the structure-based antiviral approach to
discover antiviral agents targeting the envelope glycoprotein. This approach can be divided into two
categories which are the structure-based virtual screening and the de novo ligand design (Figure 6).
Structure-based ligand optimization is often incorporated into these approaches to increase the efficacy
of the ligands. The antiviral candidates will be optimized based on the structure of their binding
pockets. The initial candidates will serve as templates from which functional groups will be added to
the candidate compounds to improve affinity and specificity to the target binding site.
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Figure 6. Structure-based dengue antiviral design. There are two approaches in structure-based
antiviral design which are the structure-based ligand screening and the de novo ligand design. (A) In
the structure-based ligand screening (virtual screening), molecular docking will be performed to
identify compounds that can bind to the target binding site (circled). Thereafter, the compound hits will
be assessed through in vitro assays such as antiviral assay. (B) In the de novo ligand design, compounds
will be designed computationally to fit the target binding site (circled). Thereafter, in vitro assays will
be performed to evaluate the antiviral activities of the compounds. Both approaches often require
structure-based optimization to improve druggability and efficacy.
5.1. Structure-Based Virtual Screening for Small Molecule Compounds Targeting the Hydrophobic Pocket in the
E Protein
The existing structural and functional information of DENV E protein has facilitated the screening
for DENV antivirals [109–113]. In particular, the crystal structure of the E protein ligand-binding
pocket occupied by a detergent molecule n-octyl-β-D-glucoside (β-OG) has inspired many researchers
to screen for molecules that could target this pocket (Figure 7) [85]. The β-OG binding altered the
conformation of the kl hairpin, which shifted towards the dimer interface, forming a salt bridge and a
hydrogen bond with the amino acids of its dimer partner [85]. The hydrophobic pocket was proposed
to act as a hinge point in the fusion-activating conformational change upon pH reduction. Compounds
blocking the hydrophobic pocket were postulated to interfere with conformational changes in the E
protein during DENV–host membrane fusion [109–113].
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Figure 7. The superimposition of the structures of DENV2 E protein in the absence (ribbon) and
presence (tube) of a detergent molecule. (A–C) The detergent molecules β-OG are shown in black. The
domains of the E protein were labelled as EDI, EDII and EDIII, and colored as red, yellow and blue,
respectively. The fusion loop is indicated by an arrow and labelled. The kl hairpin is labelled. The key
difference between the two structures is the position of the kl hairpin. (B) In the presence of detergent,
the kl hairpin will open up the hydrophobic pocket under the kl hairpin and the detergent can bind
to the hydrophobic pocket (PDB ID: 1OAM). (C) In the absence of detergent, the kl hairpin is in the
“closed position” and the hydrophobic amino acids are buried in the pocket (PDB ID: 1OAN). The
figure was modified from Modis et. al. (2003) [85].
Importantly, the study to evaluate DENV2 resistance towards compounds targeting the
hydrophobic pocket revealed that the natural barrier to resistance might be high for these
compounds [106]. Only one mutation (M196V) within the hydrophobic pocket was identified after more
than ten passages with eight individual compounds [106]. This indicates that this pocket is suitable
to be a drug target as it has a low mutation rate. Sequence analysis revealed that the hydrophobic
pocket is highly conserved in all four DENV serotypes [85]. The four DENV serotypes possess identical
hydrophobic amino acids V130, L135, F193, L198, and F279 that form the hydrophobic pocket. Thus,
drugs targeting the hydrophobic pocket might be able to neutralize all four DENV serotypes.
Researchers have performed molecular docking to screen databases containing more than 100,000
compounds for binding towards the β-OG pocket [109–113]. Subsequently, they performed various
antiviral activity and fusion inhibition assays to screen for compounds with anti-DENV activity
in vitro [109–113]. Biophysical techniques such as nuclear magnetic resonance (NMR) were utilized to
measure the interactions of the compounds with the dimeric or trimeric E protein [110].
The earliest study using this approach was performed by Yang et. al. (2007), whereby molecular
docking was utilized to screen for medicinal compounds against the β-OG pocket followed by
DENV inhibition assays [109]. Two tetracycline derivatives, rolitetracycline and doxycycline, were
identified to exert modest inhibition of DENV propagation with IC50 of 67.1 µM and 55.6 µM,
respectively. Subsequently, compound P02 was identified from structure-based screening against
DENV E protein [110]. The antiviral activities of P02 were measured based on its inhibition of YFV
growth (IC50 of 13 µM) and replication (IC50 of 17 µM) indicating that PO2 might target the E protein
and the non-structural proteins involved in genome replication or protein synthesis. A binding study
using NMR revealed that P02 bound specifically to the β-OG pocket of purified DENV E protein.
Other compounds that have been identified from virtual screening included NITD448, A5 and
R1 [111–113]. These compounds were evaluated for their antiviral activities against DENV2 with
reported IC50 values of 6.8 µM, 1.2 µM and 4 µM, respectively. Furthermore, A5 was also evaluated
against other viruses including WNV, YFV and RSV [112]. A5 exerted potent antiviral activities against
WNV and YFV with IC50 of 3.8 µM and 1.6 µM, respectively. Some of the anti-DENV compounds
have been demonstrated to hinder DENV-host membrane fusion. For instance, A5 inhibited the low
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pH induction of syncytia (quantified as a fusion index) in infected insect cells expressing DENV E
protein on the cell surface [112]. In addition, NITD448 was shown to inhibit membrane fusion between
DENV2 and liposomes [111].
To understand the molecular basis of fusion inhibition by anti-DENV compounds, Wispelaere
et al. (2018) mapped the binding sites of several small molecule compounds, viz. 2,4-disubstituted
pyrimidine, 4,6-disubstituted pyrimidine and cyanohydrazone [106]. Using a photo-crosslinking
approach, they mapped residues 247–284 of the hydrophobic pocket to be the binding site of the
fusion inhibitors. Furthermore, mutation of a residue (M272S) within the pocket was found to abolish
the binding of the inhibitors. These data supported the model that the fusion inhibitors bind to the
hydrophobic pocket to exert their antiviral effects.
Structure-based optimization has been utilized to improve the antiviral activity of compounds
identified from virtual screening [114]. For instance, Wang et. al. (2009) performed molecular docking
coupled with antiviral assays to screen for compounds that could inhibit DENV2 in human cell
lines [114]. They identified compounds 1 and 2 to inhibit DENV replication with EC50 of 1.69 µM and
0.90 µM, respectively. Thereafter, they identified functional groups that could be substituted to improve
potency through structure-activity analysis. The synthetic chemistry efforts yielded compound 6 which
displayed enhanced potency. Compound 6 inhibited all four DENV serotypes with EC50 values ranging
from 0.068 µM to 0.496 µM. Furthermore, compound 6 also inhibited other flaviviruses such as YFV,
WNV and Japanese encephalitis virus (JEV) with EC50 of 0.47 µM, 1.42 µM and 0.564 µM, respectively.
5.2. De Novo Ligand Design Targeting the DENV E Protein
De novo ligand design approaches have also been utilized to identify new compounds targeting
the hydrophobic pocket of the E protein. Recently, Leal et. al. (2019) constructed a compound library
comprising novel compounds postulated to have the ability to bind to the hydrophobic pocket similar
to the β-OG molecule using the ligand-growing program Biochemical and Organic Model Builder
(BOMB) [115,116]. They identified the 2,4-pyrimidine scaffold as the best candidate to be further
developed as one of the molecules displayed antiviral activity in the µM range. Further optimization
using a molecular dynamic-based approach ultimately yielded two compounds 3e and 3h, with high
potency and good physicochemical properties. Both compounds were active against DENV1-4 with
EC50 values in the range of 0.39–2.5 µM.
In general, the structure-based anti-DENV design approach has yielded arrays of compounds
exhibiting low potencies against DENV and other flaviviruses such as YFV, WNV and JEV (Table 2).
Only compounds 6, 3e, and 3h demonstrated modest in vitro potencies in the high nM range which
are comparable to the approved drugs against HCV infection such as sofosbuvir (Ki: 0.42 µM) [69].
Therefore, screening and design of more compounds are required to discover compounds with higher
potency in the low nM to pM range. Furthermore, the atomic structure of antiviral compounds in
complex with the hydrophobic pocket is yet to be determined. Atomic structures of the complexes are
imperative to optimize the affinity and specificity of the compounds towards the hydrophobic pocket
which may enhance the overall potency of promising compounds. It is also important to note that
the potency of compounds targeting the E protein is lower than the overall potency of compounds
targeting DENV multi-functional enzymes such as NS3 and NS5 proteins. However, the discovery
of antivirals targeting the E protein should not be abandoned as a combination of drugs targeting
multiple DENV enzymes and structural proteins might be required to formulate an effective regimen
to treat DENV infection.
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Table 2. Antiviral compounds targeting the E protein.
Compound SerotypeInhibited IC50 (µM) EC50 (µM)
Other Flaviviruses
IC50 or EC50 (µM)
Ref
Rolitetracycline DENV2* 67.1 N/A N/A [109]
Doxycycline DENV2* 55.6 N/A N/A [109]
P02 N/A N/A N/A YFV, IC50: 13–17 [110]
NITD-448 DENV2* 6.8 N/A N/A [111]
A5 DENV2* 1.2 N/A WNV, IC50: 1.6YFV: IC50: 3.8
[112]
R1 DENV2* 4 N/A N/A [113]
Compound 1 DENV# N/A 1.69 N/A [114]
Compound 2 DENV# N/A 0.90 N/A [114]
Compound 6 DENV1-4 N/A
DENV1: 0.108
DENV2: 0.068
DENV3: 0.496
DENV4: 0.334
YFV, EC50: 0.47
WNV, EC50: 1.42
JEV, EC50: 0.564
[114]
3e DENV1-4 N/A
DENV1: 0.87
DENV2: 0.85
DENV3: 0.56
DENV4: 2.5
N/A [116]
3h DENV1-4 N/A
DENV1: 0.58
DENV2: 0.81
DENV3: 0.39
DENV4: 0.87
N/A [116]
* The only serotype evaluated. #The DENV serotype evaluated was not mentioned. N/A: Not available or
not applicable.
There are several key challenges associated with the structure-based antiviral compound discovery.
Firstly, this approach is mainly effective to identify compounds with promising antiviral activities,
while the absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction remains
a problem [117]. Nonetheless, various computational methods are currently being incorporated in
the structure-based drug design to improve ADMET prediction [118,119]. Secondly, the flexibility of
target molecules remains a hurdle for molecular docking. Several approaches have been proposed
to minimize this problem such as soft docking and induced-fit docking [120–122]. However, these
approaches could not simulate large conformational changes efficiently. Therefore, other techniques
such as molecular dynamics simulation should be incorporated into virtual screening to improve the
efficiency of the screening. The incorporation of molecular dynamics was proven to be useful as the
study incorporating molecular dynamics identified two of the most potent anti-DENV compounds 3e
and 3h [116].
6. Structure-Based Discovery of Anti-DENV Peptides Targeting the E Protein
The use of peptides as antiviral agents is an attractive alternative especially with the success of
FDA-approved enfuvirtide. There are also other initiatives such as the Virus Pathogen Resource (ViPR)
that support the sequence-based predictions of antiviral peptides. Despite the number of peptides with
potent antiviral activity being low, further research in this field is warranted as there is a possibility
of discovering highly potent antiviral peptides similar to enfuvirtide with potency in the pM range.
Additionally, antiviral peptide research will increase the repertoire of drugs targeting the structural
and non-structural proteins of DENV. This will contribute to the drug combination approach to treat
DENV infection.
6.1. De Novo Design of Antiviral Peptides against DENV Infection
The de novo design approach has been used to develop peptides that can inhibit DENV. For instance,
several short peptides targeting the hydrophobic pocket of the E protein were designed using this
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approach [123]. A two amino acid glutamic acid-phenylalanine (EF) peptide displayed the highest
in vitro antiviral activity against DENV2 with an IC50 of 96.50 µM [123]. However, it exhibited weak
inhibition against the other three DENV serotypes. In another study, BioMoDroid was utilized to
design antiviral peptides to target the EDIII of DENV2 [124,125]. Two peptides, DET2 and DET4,
exhibited inhibition of DENV2 with IC50 of 500 µM and 35 µM, respectively. Visualization using
transmission electron microscopy showed that the surface of the virus particles treated with either of
the peptides became uneven with rough edges distinct to the smooth outer surface of the untreated
viral control. The disruption of the envelope structure potentially impeded viral attachment and entry.
Several peptides were designed based on the non-native sequences derived from the E protein regions
that are highly stable with regards to the structure and binding as evaluated by an all-atom scoring
function (RAPDF) [126]. RAPDF evaluated the substitution of each amino acid in the selected region
with each of the 19 naturally occurring amino acids. This approach identified four E protein regions
with the potential for the highest stability and in situ binding affinities. The 1OAN1 peptide, which
corresponded to the amino acids 41–60 of the E protein exhibited the most effective DENV2 inhibition
with an IC50 of 7 µM and maximum inhibition of 99% at the concentration of 50 µM [126].
6.2. Rational Design of Anti-DENV Peptides Based on the Structure of the E Protein
In the structure-based rational design approach, researchers designed new peptides mimicking
the specific regions in DENV such as the envelope glycoprotein, capsid protein and viral enzymes
based on the available 3D structures. The E glycoprotein can be used as a template to design anti-DENV
peptides considering our extensive knowledge of its function during DENV attachment and fusion.
There are arrays of peptides derived from several regions of the E protein including the stem region
and EDIII [100,126–129]. These peptides have been found to either directly interact with the E protein
to disrupt the viral particle and fusion or by occupying the host cell surface receptors.
Based on the knowledge that the stem region is folding back towards EDII during membrane
fusion, stem-derived peptides have been evaluated for their antiviral activities. A peptide derived
from the sequence of the stem region named DN59, inhibited more than 99% of infection by DENV2
and WNV at a concentration of less than 25 µM [127]. The ability of DN59 to cross-inhibit WNV
highlighted another advantage of using peptides as antivirals. Peptides that are derived from highly
conserved regions across several viruses could potentially inhibit other viruses in the same family as
well. In addition, the peptide exhibited broad antiviral activities against all four DENV serotypes [128].
The direct interactions of DN59 with the viral particles formed holes in the envelope and led to the
release of the RNA genome. Intriguingly, the mechanism of action of DN59 is not as expected because
stem-derived peptide should only bind to the virion after the dimeric E protein rearranged to form
trimers in the low pH environment of an endosome. Nonetheless, there is a possibility that the peptide
was able to access its binding site at the dimeric prefusion virions through the dynamic breathing of
the virus particle at 37 ◦C [130–132].
Another group also designed antiviral peptides based on the stem region of DENV E protein [129].
In contrast to DN59, these peptides were shown to bind specifically to the trimeric E protein and blocked
viral fusion. A two-step inhibition mechanism was hypothesized [129,133]. Firstly, the peptides form
reversible non-specific contacts with the viral membrane, bringing the virion-bound peptides into
the endosome. Secondly, the peptides within the endosome bound specifically and tightly to the
binding site at the conformational intermediate of the E protein during the fusion, ultimately blocking
membrane fusion.
In addition, researchers have designed antiviral peptides to block the interaction of viral particles
with cellular receptors. In a study to understand the interactions of EDIII with integrinβ3, two peptides,
P4 and P7, were designed based on the amino acids of EDIII at the FG loop [100]. The two peptides
exhibited antiviral activities against DENV2 in a dose-dependent manner with IC50 of 19 µM and
13 µM, respectively. Binding studies revealed that both peptides were able to bind to integrin β3.
Subsequent entry inhibition assays revealed that P7 could inhibit the entry of both DENV1 and DENV2.
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In contrast, P4 only inhibited the entry of DENV2 but not DENV1. This highlighted the complexity of
designing a peptide to inhibit all four DENV serotypes.
6.3. Structure-Based Optimization of Antiviral Peptide Candidates
The peptides that showed minimal antiviral activities could be further optimized using the de
novo approach. In this approach, computational optimization using programs such as RAPDF was
utilized to identify possible amino acids within the peptide that could be substituted to improve
binding to their targets [134]. For instance, two peptides corresponding to the overlapping amino
acids 205–223 (DN57) and amino acids 205–232 (DN81) within the EDII hinge region did not show
substantial DENV inhibition [127]. In contrast, analogous West Nile virus EDII hinge region peptide
potently inhibited WNV infection [127]. After computational optimization, DN57opt and DN81opt
were scored by RAPDF to have improved structural stability and in situ binding when compared
to the wild type sequences [126,134]. Both peptides displayed improved DENV inhibitory activities
than the wild-type, with DN57opt and DN81opt exhibiting IC50 values of 8 µM (14-fold increase) and
36 µM (2-fold increase), respectively. Cryo-EM revealed that DN57opt changed the surface of the
virions. This indicated that the mechanism of inhibition is most likely through the displacement of the
EDII hinge region, leading to the trapping of the viral E protein in certain conformations that were
unfavorable for viral binding and entry.
In general, the anti-DENV peptides displayed lower potencies (>2 µM) than the small molecule
compounds targeting DENV E protein and enzymes (sub µM range) (Table 3). Furthermore,
the potencies of these peptides were significantly lower than the potency of enfuvirtide, which
inhibited HIV-1 infection with an IC50 value of 100 pM [135]. Nonetheless, modifications of the
peptides such as the addition of a cholesterol moiety could improve their potency. This strategy
was successful during the development of C34 against HIV and a 36-mer peptide against human
parainfluenza, Hendra virus and Nipah virus [136,137]. Cholesterol tagging improved the potency
of these peptides by enhancing the local concentration of the peptides at the membrane fusion site
and the half-life of a peptide through its interactions with serum proteins [138]. Additionally, it was
observed that chemical compounds targeting the E protein displayed a broader spectrum of activity
against the four DENV serotypes than the antiviral peptides. This is likely due to the larger molecular
size of peptides resulting in greater specificity for their binding sites. Thus, the design of DENV
antiviral peptides should consider the amino acid sequence conservation among the four DENV
serotypes to enhance their antiviral spectra. Despite their lower potencies and narrow spectra, the
development of antiviral peptides against the four DENV serotypes is warranted. They have several
advantages over chemical compounds as they have low toxicity, easy to synthesize and have low
off-target effects due to their specificity and selectivity. Additionally, the molecular target on the
E protein such as the binding site of the stem region is too large to be accommodated by chemical
compounds. Therefore, high molecular weight biological molecules such as peptides are required
to target the large protein-protein interaction sites. Besides that, chemical compounds are highly
susceptible to viral resistance through mutations at the binding site. In contrast, peptides exhibited
a higher barrier to resistance which is likely due to their extensive interactions with multiple amino
acids on the target binding site [139].
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Table 3. Antiviral peptides targeting the E protein or mimicking the action of the E protein.
Peptide Sequence IC50 (µM)
Serotype
Inhibited Ref
EF EF 96 2 [123]
DET2 PWLKPGDLDL 500 2* [124]
DET4 AGVKDGKLDF 35 2* [124]
1OAN1 FWFTLIKTQAKQPARYRRFC 7 2* [126]
DN59 MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY 2–5 1,2,3,4 [127,128]
DV2413–447 AILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAA N/A 2* [129]
P4 CKIPFEIMDLEKRHV 19 2# [100]
P7 GVEPGQLKLNWFKK 13 1, 2# [100]
DN57opt RWMVWRHWFHRLRLPYNPGKNKQNQQWP 8 2* [126]
DN81opt RQMRAWGQDYQHGGMGYSC 36 2* [126]
*The only serotype evaluated. #Only evaluated against DENV1 and 2. N/A: Not available or not applicable.
7. Conclusions
Dengue is one of the most important infectious diseases causing significant public health threats.
Therapeutic drug development will remain important since there is no clinically approved antiviral
drug and the only licensed vaccine, Dengvaxia, is shrouded in controversy. Although no antiviral
agent has been demonstrated to be effective against acute dengue in clinical trials, the pre-clinical
research pipeline contains many antiviral agents that are promising. The availability of the DENV E
protein structure has provided a foundation for structure-based drug discovery to identify antivirals
against DENV. However, many of the antiviral agents have not been further developed. This is due
to their low potency, poor pharmacokinetic properties and their inability to inhibit all four DENV
serotypes. Therefore, future studies should prioritize the in vitro and in vivo evaluations of antiviral
candidates against all four DENV serotypes. The ADMET and viral resistance of these candidates need
to be established before their efficacies can be evaluated in clinical trials. More importantly, most of the
compounds and peptides require further optimization to increase their potencies to be comparable
to the potency of other clinically approved antiviral drugs. Although most of the current antiviral
candidates will not enter clinical trials due to their low to modest potencies, these antivirals have
provided a platform for future discovery of highly potent anti-DENV agents.
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